Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2021
Press release – For immediate release – 5:45 pm CET
Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2021 pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
|Total number of shares||15,472,949|
|Number of real voting rights* (excluding treasury shares**)||15,424,216|
|Theoritical number of voting rights* (including treasury shares**)||15,449,749|
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median has received the “Innovative Company” label from BPI France, is eligible for the French SME equity savings plan scheme (PEA-PME), is listed on the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label.
Head of Corporate and Marketing Communications
+33 6 10 93 58 88
+33 1 56 88 11 11
Alizé RP (Press)
+33 6 64 18 99 59